课题基金 / 基金详情

UT Southwestern: Clinical Site for the Drug-Induced Liver Injury Network

UT Southwestern: Clinical Site for the Drug-Induced Liver Injury Network
德州大学西南医学中心:药物性肝损伤网络临床​​站点
批准号:
8132960
负责人:
William M Lee
金额:
$25.97万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-09-30 至 2013-06-30

项目摘要

项目成果

William M Lee的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Drug-induced liver injury (DILI) is one of the most difficult problems encountered in clinical medicine. Unexpected DILI has hampered drug development for a multitude of effective drugs. Many agents have been approved or nearly approved but failed to gain widespread acceptance because of severe and sometimes fatal DILI. The small size of pre-approval trials means that infrequent events will not be captured. Thus, aggressive, robust, and measured approaches to post-marketing surveillance for adverse events due to drugs and their characterization is vital to the health of all Americans. The Drug-Induced Liver Injury Network (DILIN) has made a strong start in laying the groundwork in its first 5 years, having put in place systems that can be used more widely in the future. Thus, an opportunity exists to enhance capture of additional cases of post-marketing DILI so as to improve our understanding of its causes and. potentially, its treatment. UT Southwestern is ideally suited to become a DILIN site for the following reasons: 1) the Dallas Fort Worth metroplex constitutes a widely diverse urban/suburban population of over 6.5 million people. 2) the investigators have specific and strong experience in DILI and clinical trials development, Our specific proposals include: 1) An advisory board of clinicians in the region to refer cases. We will consult them frequently, provide a 1-800 number for their calls and visit sites for in service updates and discussion of drugs of importance in causing DILI. 2) We will utilize the experience of the investigators in the Acute Liver Failure Study to expand and encourage further ancillary studies utilizing DILI biomaterials. Specific substudies should be possible with the large Hispanic population currently under study at our institution. 3) We propose a therapeutic trial using N-acetylcysteine for DILI cases that meet criteria for severe injury approximating Hy Zimmerman's law, that is, an acute illness with attendant jaundice.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
North Texas Hepatitis B Consortium: Clinical Site for the Hepatitis B Network
  • 批准号:
    8141217
  • 项目类别:
  • 资助金额:
    $34.17万
  • 财政年份:
    2008
  • 负责人:
    William M Lee
  • 依托单位:
North Texas Hepatitis B Consortium: Clinical Site for the Hepatitis B Network
  • 批准号:
    8730129
  • 项目类别:
  • 资助金额:
    $35.87万
  • 财政年份:
    2008
  • 负责人:
    William M Lee
  • 依托单位:
UT Southwestern: Clinical Site for the Drug-Induced Liver Injury Network
  • 批准号:
    7591876
  • 项目类别:
  • 资助金额:
    $24.52万
  • 财政年份:
    2008
  • 负责人:
    William M Lee
  • 依托单位:
North Texas Hepatitis B Consortium: Clinical Site for the Hepatitis B Network
  • 批准号:
    7932256
  • 项目类别:
  • 资助金额:
    $49.66万
  • 财政年份:
    2008
  • 负责人:
    William M Lee
  • 依托单位:
海外基金